Digital health technology firm Global Kinetics has secured CE mark approval for its second generation Parkinson’s KinetiGraph (PKG) system.
The PKG is an algorithm-based system, which records body movements and other symptoms over the course of seven days and creates data-driven reports, helping to take more personalised treatment and management decisions.
The second generation system features a modern design for the wrist worn device called PKG watch.
The PKG watch, which is similar to a smart watch, includes a vibrating alarm and LED light for medication reminders.
The new system has also obtained approval from the US Food and Drug Administration (FDA), as well as trialled in Australia.
It helps patients to monitor their condition round the clock, and clinicians to secure detailed reports of the patient’s movements, to evaluate the impact of the disease on the patient’s everyday life.
The company intends to initially introduce the new technology in 12 European movement disorder clinics in the next two months, and later full rollout to be used for patients and clinicians.
The first generation PKG system is already used in multiple countries across Europe including Sweden, Finland, Germany, France, Netherlands and the UK.
Global Kinetics CEO and president Timothy Still said: “Global Kinetics continues to deliver on its strategic business objectives while remaining steadfast in our mission to make a meaningful difference for people with Parkinson’s.
“We recently celebrated delivery of our 13,000th PKG report – and look forward to a new era of impact for patients around the world with our second generation PKG system.
Image: The PKG watch includes a vibrating alarm and LED light for medication reminders. Photo: courtesy of Global Kinetics Corporation.